OBJECTIVE: To find out clinical features, diagnostic techniques and management outcome of @entity1 having @entity779 and @entity281 . STUDY DESIGN: A case series. PLACE AND DURATION OF STUDY: Medical Unit-III, Ward- 7, Jinnah Postgraduate Medical Centre, Karachi, from September 2007 to January 2008. METHODOLOGY: @entity1 presented with @entity221 of less than or equal to 10 days duration, severe @entity1053 aches, @entity1910 and @entity548 manifestations were included. @entity1 with obvious features of other diseases like @entity1682 , @entity548 and @entity1583 and only @entity4801 positive with high grade intermittent @entity221 without @entity1910 and @entity925 were excluded from the study. Diagnosis of @entity779 and @entity311 was based on history, clinical features, laboratory parameters and @entity4801 test by thin and thick films. Serological evaluation was done by @entity779 IgM and IgG by ELISA test kit. @entity1 were divided into three groups. Group A was @entity779 IgM positive plus @entity2468 positive, group B was @entity779 IgM positive and @entity2468 negative and group C was @entity779 IgM negative and @entity2468 negative and were clinically suspected @entity779 and @entity311 . The clinical manifestations and laboratory parameters of @entity779 and @entity311 positive @entity1 were compared with @entity311 and @entity779 @entity1 . RESULTS: One hundred and fourteen @entity1 were seen during the study period. Antibody titer (IgM) tested in all @entity1 was found positive in 78 @entity1 (69.64%). Among those 78 @entity1 , 26 (23.21%) were concomitantly positive for @entity4801 (Group A). @entity3965 was positive in 25 @entity1 and @entity9231 in one @entity1 . Fifty-two @entity1 (46.42%) were @entity779 IgM positive and @entity2468 negative (Group B). Thirty four (30.35%) @entity1 were @entity2468 and @entity779 IgM negative (Group C) but were strongly suspected for DHF and @entity311 on clinical and hematological basis. The hemoglobin of 34.61% of @entity1 of group A, 5.76% of group B and 14.7% of group C were low, hematocrit level was also low in group A (92.3%), group B (15.38%) and group C (70.58%) @entity1 . The platelet count was markedly low in 84.61% of @entity1 of group A, 57.69% of group B and 94.11% of group C. @entity1431 was found in 34.61% of @entity1 of group A, 78.84% in group B and 29.411% in group C. The liver function tests were deranged in all groups. CONCLUSION: The frequency of @entity779 and @entity281 was 23.21%. The serology of the @entity779 and @entity311 showed negative results in 30.35%. The diagnosis of @entity281 could be made on the basis of history, clinical examination supported by hematological results. It is recommended that all the @entity1 suspected for @entity281 should be treated concomitantly for @entity779 and @entity311 in @entity311 endemic areas.

Clinical features, diagnostic techniques and management of XXXX and @entity281 .

@entity1 :: ('9606', 'Species') :: ['patient', 'Patients', 'patients'] @entity1910 :: ('MESH:D005076', 'Disease') :: ['rash'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding', 'hereditary bleeding diathesis'] @entity2468 :: ('MESH:C535959', 'Disease') :: ['MP'] @entity3965 :: ('5855', 'Species') :: ['Plasmodium vivax'] @entity281 :: ('MESH:D007239', 'Disease') :: ['malaria infection', 'dual infections'] @entity9231 :: ('MESH:D016778', 'Disease') :: ['falciparum'] @entity1053 :: ('MESH:D001835', 'Disease') :: ['body'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematological malignancies'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['Leukopenia'] @entity4801 :: ('MESH:D010272', 'Disease') :: ['malarial parasite'] @entity311 :: ('MESH:D008288', 'Disease') :: ['malaria'] @entity779 :: ('MESH:D003715', 'Disease') :: ['dengue', 'dual dengue', 'dengue negative'] @entity925 :: ('MESH:D063806', 'Disease') :: ['myalgia'] @entity221 :: ('MESH:D005334', 'Disease') :: ['fever'] @entity1682 :: ('MESH:D014435', 'Disease') :: ['typhoid']
@entity779 :: (MESH:D003715,Disease) :: ['dual dengue']
